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1.	Abstract	
	
	 Hematogenous	metastasis	causes	90%	of	breast	cancer-related	deaths.1	Current	
therapies	include	chemotherapy	and	irradiation	following	surgery.	These	therapies	are	very	
harmful	to	the	human	body	and	do	not	elicit	an	anti-tumor	immune	response.	To	create	a	novel	
therapeutic,	an	autologous	vaccine	increasing	the	immunogenicity	of	non	immunogenic	breast	
cancer	cell	lines	has	been	proposed.			
	 To	create	this	vaccine,	4T1	mouse	mammary	breast	cancer	cells	have	been	selected	as	
the	desired	cell	line	to	treat.	They	are	non	immunogenic	and	highly	invasive.	In	order	to	
increase	their	immunogenicity,	first	projected,	was	the	addition	of	cytokines	to	4T1	cells	to	
increase	the	expression	of	immunostimulatory	molecules	on	the	cells.	TNF-α	and	IFN-γ,	two	
pro-inflammatory	cytokines,	were	added	individually	at	a	concentration	of	50ng/mL	to	4T1	
cells.	This	concentration	was	chosen	based	on	an	MTS	viability	assay	and	ensures	that	the	
cytokines	themselves	are	not	killing	the	cells	before	an	immune	response	is	stimulated.	Flow	
cytometry	was	used	to	evaluate	the	surface	marker	expression	of	major	histocompatibility	
complex	(MHC)	I,	MHC	II,	B7.1,	B7.2,	ICAM,	and	Fas.	There	was	a	minimal	effect	on	each	MHC	
and	co-stimulator	molecule	resulting	from	TNF-α.	IFN-γ	developed	in	an	increase	in	ICAM	and	
MHC	II.	Neither	of	the	cytokines	created	a	large	enough	increase	to	have	a	large	effect	on	the	
immunogenicity	of	4T1	cells.	Therefore,	protein	expression	of	4T1	cells	was	reviewed.	
	 4T1	cells	express	G-CSF	in	large	amounts	which	causes	myeloid	derived	suppressor	cells	
(MDSCs)	to	accumulate	within	the	spleen	of	a	mouse.	These	MDSCs	produce	mature	T	cells	
although	with	high	levels	of	G-CSF	expressed	they	remain	in	the	spleen	undifferentiated.	G-CSF	
was	knocked	out	using	CRISPR/Cas9	methods	in	order	to	increase	the	immunogenicity	of	4T1	
cells.	The	4T1.GCSF-	cell	line	underwent	single	colony	expansion	and	the	concentration	of	G-CSF	
within	the	cell	line	was	examined	using	ELISA	(n=3).	After	single	colony	expansion,	G-CSF	was	
undetectable	in	the	4T1.GCSF-	cell	line.		
	 Next,	the	4T1.GCSF-	cell	line	will	be	used	in	an	in-vivo	prophylactic	vaccination.	100,000	
4T1.GCSF-	cells	will	be	irradiated	and	subcutaneously	inserted	into	the	mice	as	a	primary	
vaccine	on	day	0	and	a	booster	on	day	10.	On	day	20	the	mice	will	be	challenged	with	live	4T1	
cells	and	the	tumor	volume	will	be	measured	three	times	per	week.	
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2.	Summary	 	
The	past	two	years	I	have	worked	in	Dr.	David	Zaharoff’s	Laboratory	for	Vaccine	and	
Immunotherapy	Delivery	(LVID).	During	my	time	in	Dr.	Zaharoff’s	lab	I	have	been	working	under	
the	direction	of	Ph.D.	candidate,	Sruthi	Ravindranathan.	Through	my	time	in	Dr.	Zaharoff’s	lab	I	
have	worked	on	two	projects,	both	geared	toward	creating	an	autologous	breast	cancer	vaccine	
for	triple	negative	breast	cancer	(TNBC)	strands.	“TNF-α	and	IFN-γ	Immunomodulation	of	Breast	
Cancer	Cells	for	Whole	Tumor	Cell	Vaccine”	was	my	first	project	which	included	adding	
cytokines	to	a	triple	negative	mouse	mammary	cancer	cell	line,	4T1,	in	efforts	to	create	a	
vaccine.		The	addition	of	cytokines	to	4T1	cells	was	performed	in	hopes	of	increasing	the	
immunogenicity	of	this	cell	line.	An	appropriate	concentration	at	which	the	cytokines	would	be	
added	was	determined	from	MTS	viability	testing.	Flow	cytometry	was	used	to	evaluate	the	
increase	in	immunogenicity	of	4T1	cells	by	testing	the	surface	marker	expression	of	major	
histocompatibility	complex	I	(MHC	I),	MHC	II,	and	several	co-stimulatory	molecules.	4T1	cells	
alone,	4T1	cells	with	irradiation,	4T1	cells	with	50ng/mL	of	the	cytokine,	and	4T1	cells	with	
50ng/mL	of	the	cytokine	and	irradiation	were	all	tested	for	each	cytokine.	It	was	concluded	that	
TNF-α	has	a	minimal	effect	on	the	surface	marker	expression	of	4T1	cells	and	IFN-γ	has	an	
effect	on	several	co-stimulatory	molecules	although	not	enough	to	increase	the	
immunogenicity	of	the	cell	line.	
“G-CSF	Knockdown	Immunomodulation	of	Breast	Cancer	Cells	for	Whole	Tumor	Cell	
Vaccine”	is	my	second	project.	During	this	project	I	used	CRISPR/Cas9	to	knock	out	granulocyte	
colony	stimulating	factor	(G-CSF)	to	create	4T1.GCSF-.	G-CSF	was	removed	to	decrease	the	
amount	of	myeloid	derived	suppressor	cells	(MDSCs)	accumulating	at	abnormally	increased	
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rates	in	the	spleen	of	a	mouse	when	4T1	tumor	formation	occurred.	MDSCs	differentiate	into	
mature	immune	cells.	By	regulating	G-CSF,	the	MDSCs	will	differentiate	into	monocytes	or	
granulocytes	at	a	normal	rate,	thus	the	4T1	cell	line	would	increase	its	immunogenicity.	G-CSF	
was	successfully	removed	from	the	cell	line	by	use	of	CRISPR/Cas9	and	single	colony	expansion.	
Next,	4T1.GCSF-	will	be	used	in	an	in-vivo	prophylactic	vaccination	to	examine	the	effects	of	
knocking	out	G-CSF	on	the	cell	line’s	immunogenicity	within	mouse	models.	
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3.	Introduction:	
3.1	Significance	of	Work:		
Hematogenous	metastasis	is	responsible	for	9	of	10	breast	cancer-related	deaths.1	
Currently,	to	reduce	this	large	fraction	of	deaths,	adjuvant	therapies	such	as	chemotherapy	and	
radiation	are	given	following	a	mastectomy	or	lumpectomy	surgery.2	These	therapies	are	very	
harmful	to	the	body,	regarding	their	high	levels	of	toxicity,	hence	a	novel,	safer	therapy	is	
needed.2	Immunogenic	therapies	using	one’s	own	cancer	cells	to	remove	any	residual	tumor	
cells	is	an	innovative	approach	for	an	original,	personalized	therapeutic.		
3.2	Background:	
4T1	mammary	carcinoma	is	a	highly	aggressive	and	invasive	mouse	breast	cancer	cell	
line.	These	cells	are	a	very	useful	tumor	model	and	metastasize	to	multiple	distant	sites	
compared	to	many	other	breast	cancer	cell	lines,	such	as	lymph	nodes,	blood,	brain,	and	
bone.2,3	4T1	cells	are	very	useful	in	the	laboratory	setting	because	they	have	many	
characteristics	comparable	with	human	mammary	breast	cancer	including	spontaneous	
metastases	development	and	ease	of	transplanting	into	mammary	gland.3		
In	addition,	4T1	cells	are	completely	non-immunogenic.4	Non-immunogenic	cell	lines	are	
also	known	as	triple	negative	breast	cancer	cells.	They	lack	the	three	receptors	that	typically	
indicate	the	cause	for	breast	cancer,	estrogen	receptors,	progesterone	receptors,	and	human	
epidermal	growth	factor	receptor	2	(HER2).1	Several	breast	cancers	that	express	one	of	these	
receptors	are	targeted	based	on	the	receptor.	Due	to	4T1	cells	lacking	all	three,	finding	
therapeutics,	target	genes,	or	target	proteins	is	very	difficult.	Therefore,	research	is	constantly	
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conducted	in	order	to	provide	new	innovative	forms	of	treating	this	highly	metastatic,	non	
immunogenic	form	of	breast	cancer.		
There	are	many	forms	of	breast	cancer	cell	lines	and	they	are	characterized	by	their	
metastatic	potential	and	invasive	properties.	The	immunology	behind	breast	cancer	can	
account	for	the	metastatic	potential	of	different	cell	lines.	4T1	cells	are	non	immunogenic	
implying	there	is	no	immune	response	to	4T1	tumor	growth	or	cell	metastasis.	Other	cell	lines	
such	as	MCF-7,	which	have	a	greater	immune	response	and	will	not	metastasize.5	The	innate	
immune	system	can	detect	MCF-7	cells	using	T	cells	in	the	bone	marrow.5	The	innate	immune	
system	can	detect	multiple	viruses	and	is	non-specific	utilizing	macrophages	and	dendritic	cells	
throughout	the	body.7	The	other	form	of	immunity	is	the	adaptive	immune	system	controlled	
by	mechanisms	and	interactions	between	T	cells	and	B	cells,	two	forms	of	lymphocytes.	An	
adaptive	immune	response	requires	the	innate	immune	system	to	detect	viruses.6	B	cells	have	
receptors	which	are	able	to	detect	viruses	and	microbes.7	After	attachment	occurs	between	the	
virus	and	a	B	cell,	the	B	cell	transforms	into	a	plasma	cell	to	secrete	an	antibody.	The	antibodies	
attach	onto	virus	and	diseased	cells	to	tag	them	for	cytokinesis	by	macrophages.6	T	cells	include	
T	helper	cells	and	cytotoxic	T	lymphocytes	(CTLs).	The	T	cells	mediate	the	adaptive	immune	
system	by	recognizing	the	presentation	of	specific	peptides	on	the	surface	of	macrophages’	
major	histocompatibility	complex	(MHC)	II	surface	marker	receptors.	These	peptides	are	a	
portion	of	the	virus’	DNA.6	The	T	helper	cells	will	attach	to	the	macrophage	via	the	MHC	II	
receptor	and	produce	cytokines	to	mark	the	virus	for	phagocytosis.	The	recognition	of	MHC	II	
by	helper	T	cells	also	causes	B	cells	to	proliferate,	in	turn	creating	more	antibody-secreting	
cells.7	CTLs	enforce	automatic	phagocytosis	using	MHC	I	receptors.	Increased	proliferation	of	
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CTLs	can	cause	autoimmune	disorders	due	to	non	tumorigenic	cells	entering	phagocytosis	
spontaneously.6	
	 In	my	undergraduate	honors	thesis,	two	different	methods	of	increasing	the	
immunogenicity	of	4T1	cells	are	described.	One	entails	increasing	the	cytokine	surface	marker	
expression	of	4T1	cells	using	either	IFN-γ	or	TNF-α	in	order	to	recruit	more	T	cells	and	enable	
macrophages	to	engulf	4T1	tumor	cells.	The	other	uses	CRISPR/Cas9	to	remove	a	protein,	G-
CSF,	causing	expansion	of	myeloid	derived	suppressor	cells	(MDSCs)	within	the	spleen.			
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4.	Project	1:	TNF-α	and	IFN-γ	Immunomodulation	of	Breast	Cancer	Cells	for	Whole	Tumor	Cell	
Vaccine	
	
4.1	Introduction	
Tumor	necrosis	factor-alpha	(TNF-	α)	and	interferon-gamma	(IFN-	γ)	are	two	pro-
inflammatory	cytokines	which	have	been	shown	to	upregulate	the	expression	of	surface	
molecules	involved	in	antigen	presentation,	such	as	major	histocompatibility	complex	I	(MHC	I)	
and	II	(MHC	II),	and	immune	co-stimulators,	such	as	B7.1.8		IFN-γ	directly	regulates	MHC	II	and	
TNF-α	regulates	MHC	I,	II,	and	B7	receptors.9	By	increasing	the	expression	of	these	molecules,	
cells	interact	more	strongly	with	cells	of	the	immune	system.		These	same	cytokines	can	also	
induce	apoptosis,	or	programmed	cell	death	of	the	4T1	cell	and	surrounding	angiogenic	
endothelium	to	reduce	further	tumor	vasculature.10	An	innate	immune	response	is	desired	for	
production	of	an	autologous	vaccine.	Through	the	addition	of	cytokines	to	non	immunogenic	
4T1	cells,	the	immune	system	may	recognize	the	increased	surface	marker	expression	of	MHC	I,	
MHC	II,	or	the	several	other	co-stimulatory	molecules	expressed.		
These	surface	markers	directly	correlate	with	T	cells	in	the	body.		CTLs	present	the	MHC	I	
receptor	along	with	CD8+,	B7.1,	and	ICAM	which	bind	with	the	tumor	cells	to	increase	bonding	
strength	between	the	two	cells.6	T	helper	cells	express	the	MHC	I	receptor	and	CD4+	which	bind	
to	cancer	cells	expressing	MHC	I,	B7.2,	and	Fas	(Figure	1).6	When	IFN-γ	and	TNF-α	are	secreted	
by	T	cells,	it	increases	the	MHC	I	and	MHC	II	present	on	diseased	cells.	In	turn	CTLs	will	be	
activated	and	proliferated	to	account	for	the	needed	immune	response.10	
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Figure	1.	T	helper	cells	recognize	virus	or	disease-associated	cells	based	on	the	
presentation	of	MHC	II	on	the	surface	of	the	virus.	Co-stimulator	molecules,	B7.1	and	ICAM,	
enhance	the	attachment	strength	between	the	T	helper	cell	and	the	virus.	
	
The	objective	of	this	study	is	to	enhance	the	immunogenicity	of	a	non	immunogenic	breast	
cancer	cell	line	through	treatment	of	IFN-γ	or	TNF-α.	Cell	viability	will	be	analyzed	at	increasing	
concentrations	of	IFN-γ	or	TNF-α	when	added	to	4T1	cells.	The	expression	of	specific	surface	
molecules	involved	in	antigen	presentation	will	be	measured;	MHC	I,	MHC	II,	B7.1,	B7.2,	ICAM	
and	Fas;	in	order	to	determine	if	the	surface	molecules	are	up-regulated	with	the	addition	of	
cytokines.	Therefore,	I	hypothesize	that	exposing	4T1	cells	to	TNF-	α	or	IFN-	γ	will	enhance	their	
immunogenicity	and	form	the	basis	for	a	novel	breast	cancer	vaccine.	
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4.2	Methods	and	Materials	
4.2.1	Cell	Culture.		
The	4T1	cell	line	is	a	mouse	mammary	breast	cancer	purchased	from	ATCC.	The	cells	
were	cultured	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	media	containing	90%	DMEM	
stock,	10%	fetal	bovine	serum,	1%	Penicilin	Streptomycin,	4500mg/L	glucose,	2mM	L-glutamine,	
and	1%	sodium	pyruvate.	The	cells	were	grown	in	incubation	at	37°C	with	monitored	5%	CO2	
and	H20	levels.	The	cells	are	stored	frozen	in	a	Thermo	Scientific	Liquid	Nitrogen	container	
(Locator	4)	until	needed.	The	cell	count	doubles	in	about	24	hours.	
	
4.2.2	CellTiter	MTS	Viability	Assay.	
To	explore	the	effects	of	IFN-γ	and	TNF-α	on	viability,	4T1	cells	were	treated	with	
increasing	concentrations	of	IFN-γ	and	TNF-α	cytokines.	2000	4T1	cells	were	seeded	onto	a	96	
well	plate	with	100uL	of	DMEM	and	increasing	concentrations	of	IFN-γ	and	TNF-α,	for	24	hours.		
The	concentrations	included	50	ng/mL,	100	ng/mL,	200	ng/mL,	300	ng/mL,	400	ng/mL,	and	500	
ng/mL.	The	experiment	was	performed	in	triplicate.		
A	CellTiter	MTS	viability	assay	was	performed	on	the	4T1	cells	with	IFN-γ	and	TNF-α,	
individually.	The	MTS	reagent	was	thawed	and	the	96	well	plate	was	equilibrated	at	room	
temperature	for	30	minutes.	10	uL	was	added	to	each	well	separately	with	100uL	of	cells	and	
DMEM.	The	contents	were	mixed	on	the	orbital	shaker	for	2	minutes	without	additional	heat	at	
a	speed	of	70.	The	plate	was	incubated	for	1	to	4	hours	to	allow	for	proper	mixture	of	the	cells	
and	substrate.	The	number	of	live	4T1	cells	after	24	hours	was	assessed	using	a	BioTek	
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Instruments	Synergy	2	microplate	reader	(BioTek	Instruments,	Winooski,	VT)	and	the	
luminescent	assay.	The	plate	reader	was	read	at	490nm	with	Gen	5.1.09	computer	software.	A	
linear	equation	was	created	with	standards	in	excel	to	ensure	R2>.95.	
	
4.2.3	Live	Cell	Imaging	of	Cytokine-Treated	4T1	cells.		
Images	from	a	Nikon	Eclipse	Ti	fluorescent	microscope	with	a	10x	objective	were	taken	
of	the	cells	at	each	cytokine	concentration	and	a	percentage	was	assigned	to	each	image	to	
state	each	flask’s	confluency.	The	images	revealed	details	on	the	dispersal	of	cells	within	the	
flasks	and	the	visual	interpretation	of	these	cells	viewed	on	a	light	microscope.	Images	were	
taken	using	Nikon	NIS-Elements	BR	imaging	software.	
	
4.2.4	Flow	Cytometry	Measures	4T1	Surface	Marker	Expression.		
A	BD	FACSCanto	II	Flow	Cytometer	was	used	to	evaluate	the	expression	of	MHC	I,	MHC	
II,	Fas,	ICAM,	B7.1,	and	B7.2,	before	and	after	cytokine	exposure.	4T1	cells	alone	were	used	as	
the	control.	The	concentrations	determined	by	the	CellTiter	viability	assay	to	implement	the	
optimal	effect	of	TNF-	α	and	IFN-	γ	was	used,	50ng/mL	of	each	cytokine.	2	million	4T1	cells	were	
seeded	in	4	T75	flasks.	24	hours	later,	50ng/mL	of	either	IFN-γ	or	TNF-α	was	added	to	2	flasks.		
24	hours	after,	a	single	flask	of	cytokine-treated	4T1	cells	and	4T1	cells	alone	were	irradiated	
with	100	gray.	The	day	of	irradiation,	the	flasks	were	all	examined	using	flow	cytometry.	Each	
day	the	flasks	were	renewed	with	10mL	of	DMEM	media.		
1	million	cells	from	each	experimental	and	control	group	were	isolated	for	flow	
cytometer	use.	Flourochromes	were	used	to	detect	each	individual	MHC	or	co-stimulatory	
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molecule.	The	flourochromes	(BD	BioScience,	San	Jose,	CA)	used	include	2uL	of	FITC	mouse	
anti-mouse	H-2Kb,	5uL	of	PE	rat	anti-mouse	I-Ad/I-Ed,	5	uL	PE-Cy7	hamster	anti-mouse	CD95,	
2uL	of	FITC	hamster	anti-mouse	CD54,	5uL	of	APC	hamster	anti-mouse	CD80,	and	5uL	of	PE	rat	
anti-mouse	CD86,	for	MHC	I,	MHC	II,	Fas,	ICAM,	B7.1,	and	B7.2,	respectively.		A	negative,	
isotype	(PE	Hamster	IgG1,	k	Isotype	control),	and	untreated	cell	sample	were	calculated	for	
controls.	The	samples	were	incubated	in	dark	for	1	hour	before	compensation	controls	were	
detected	and	accounted	for.	Then	samples	were	measured	after	the	supernatant	was	removed	
and	500uL	of	PBS	was	added	to	each	tube.	When	not	being	sampled,	the	tubes	were	placed	in	
ice	to	preserve	the	cells.	A	large	increase	in	the	expression	of	these	markers	is	expected	to	
correspond	with	the	immunogenicity	of	the	tumor	cells.	Images	were	provided	by	BD	
FACSCanto	computer	software	(2.4).	FlowJo	software	was	used	to	combine	data	from	the	4	
groups	and	compare	overlay	images	of	the	results.		
	
4.3	Results	
4.3.1	Effect	of	IFN-γ	and	TNF-α	on	4T1	viability.	
An	MTS	viability	assay	(CellTiter)	was	performed	to	evaluate	the	effect	of	IFN-γ	and	TNF-
α	on	4T1	cells.	Varying	concentrations	were	evaluated	to	determine	which	concentration	would	
allow	the	cells	to	survive	and	generate	an	anti-tumor	immune	response.	2000	4T1	cells	were	
seeded	onto	a	96	well	plate	and	the	cytokines	were	added	to	each	well	for	24	hours.	The	
experiments	began	with	concentrations	of	0-100ng/mL,	increments	of	25,	and	little	effect	was	
shown.	Concentrations	were	increased	to	300ng/mL,	increments	of	50,	and	a	larger	difference	
in	viability	was	viewed.	Concentrations	were	also	examined	at	varying	time	periods,	24,	48,	and	
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72	hours,	although	there	was	no	effect	from	prolonged	exposure.	The	final	viability	assay	was	0-
500ng/mL	which	displayed	the	difference	between	IFN-γ	and	TNF-α	(Figure	2).	IFN-γ	initially,	at	
100ng/mL,	decreases	the	number	of	cells	and	levels	off	with	a	steady	increase	from	200-500	
ng/mL.	TNF-α	shows	a	steady	decrease	after	the	initial	decrease	in	cell	number.	TNF-α	has	a	
greater	effect	on	killing	4T1	cells	than	IFN-γ.	To	have	a	comparable	study	between	IFN-γ	and	
TNF-α,	the	concentration	of	the	cytokine	should	reveal	a	similar	effect.	Therefore,	50ng/mL	was	
selected	to	treat	the	4T1	cells	with,	to	examine	the	effect	of	cytokines	on	surface	marker	
expression	of	4T1	cells.		
	
	
	
	
	
	
	
Figure	2.	Comparison	of	IFN-γ	or	TNF-α	cytokines	and	their	effect	on	4T1	breast	cancer	cell	
viability.		As	stated	in	methods	section,	there	is	an	N=3	for	the	differing	number	of	cells.	
	
Images	of	each	flask	with	0-500ng/mL	concentrations	of	IFN-γ	and	TNF-α	were	captured	
to	examine	the	confluency	of	each	flask	(Figure	3).	With	increasing	concentrations,	the	
confluency	appeared	to	increase	in	the	mid	range	concentration	of	300ng/mL	and	decrease	
again	at	500ng/mL.	The	cells	appear	healthier	in	0ng/mL	and	300ng/mL	compared	to	500ng/mL	
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where	several	dark	cells	appear.	The	0ng/mL	images	also	appear	well	spread	out	and	growing	at	
normal	rates	whereas	300ng/mL	appears	very	confluent	for	after	only	24	hours	of	seeding	the	
4T1	cells.	
	
	
Figure	3.	Confluency	of	each	4T1	well	after	24	hours	is	shown	with	a	corresponding	confluency	
percentage.		Both	IFN-γ	and	TNF-α	treated	cells	at	different	concentrations	are	compared	with	
control	cells.		Images	are	taken	with	a	fluorescent	microscope,	10x	lens.	
	
4.3.2	Effect	of	IFN-γ	and	TNF-α	on	surface	marker	expression.	
500,000	cells	of	each	cytokine-treated	cell	line	was	used	to	test	expression	of	surface	
molecules.	50ng/mL	of	each	cytokine	was	added	to	4T1	cells.	A	6-color	flow	cytometer	
measured	different	fluorochromes	(FITC,	APC,	PE,	PE-Cy7)	to	test	the	surface	marker	expression	
60% 60% 80% 
TNF-α	 
IFN-γ 
60% 70% 70% 
0	ng/mL 500	ng/mL 300	ng/mL 
 16 
of	B7.1,	B7.2,	ICAM,	Fas,	MHC	I,	and	MHC	II.		The	co-stimulator	and	MHC	molecules	were	
chosen	due	to	their	immune	system	connection	with	CTLs	and	T	helper	cells.	4T1	cells	alone	and	
4T1	cells	alone	with	irradiation	were	used	as	controls.	4T1	cells	with	50ng/mL	of	the	selected	
cytokine	and	4T1	cells	with	50ng/mL	of	the	selected	cytokine	and	irradiation	were	compared	to	
the	controls.	IFN-γ	provided	an	increase	of	FITC	and	MHC	II	(Figure	4).	Based	on	the	difference	
in	the	flow	cytometry	results	there	is	not	a	large	enough	different	in	surface	marker	expression	
for	the	alternate	molecules	to	have	an	effect	on	4T1	cells’	immunogenicity.	An	increase	in	two	
of	the	molecules	tested	will	not	elicit	an	immune	response.	TNF-α	had	a	very	minimal	effect	in	
increasing	any	surface	marker	expression	(Figure	4).	There	is	a	small	separation	in	peaks	for	all	
molecules	tested	although	not	enough	to	have	a	difference	in	4T1	immunogenicity,	as	stated	
for	IFN-γ.	Therefore,	50ng/mL	of	neither	cytokine-treated	4T1	cells	had	an	effect	on	surface	
marker	expression.	Multiple	time	periods,	24	hrs,	48	hrs,	and	72hrs,	were	tested	to	detect	if	
there	was	a	difference	in	surface	marker	expression	although	no	difference	was	seen,	similar	to	
previously	results	seen	in	cell	viability.			
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IFN-γ	
TNF-α	
	
		 4T1	Cells	Alone	 		 4T1	Cells	+	50ng/mL	TNF-α	
		 4T1	Cell	+	Irradiation	 		 4T1	Cells	+	50ng/mL	TNF-α	+	Irradiation	
	
Figure	4.	Flow	Cytometry	result	comparison	of	50ng/mL	TNF-α	and	IFN-γ	treated	4T1	cells.	
There	was	a	control	group	for	irradiated	cells	alone,	cells	alone,	and	50ng/mL	of	the	cytokine	
alone	and	with	irradiation.	Image	overlay	was	created	with	FlowJo	software.	
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4.4	Discussion	and	Future	Work.	
						The	500ng/mL	concentration	of	TNF-α	results	in	a	73%	lesser	cell	survival	rate,	compared	to	
the	control	(Figure	4).	This	percentage	indicates	the	cells	will	die	as	a	result	from	cytokine	
treatment	but	not	necessarily	due	to	increased	surface	marker	expression	or	an	innate	immune	
response.	If	the	surface	marker	expression	on	these	cells	were	to	increase,	it	would	likely	
produce	an	immune	response5,6,7.	If	the	concentration	of	cytokines	were	to	increase	more	than	
50ng/mL	the	cell	survival	would	decrease	(Figure	4).	If	enough	cytokines	are	expressed,	the	cell	
will	die	although	not	due	to	an	anti-tumor	immune	response	but	due	to	overproduction	of	
cytokines.	The	in	vitro	study	aims	to	mimic	the	immune	system	in	the	body	and	the	large	
concentrations	of	cytokines	are	not	realistic	if	the	4T1	cells	are	undetectable	by	the	immune	
system.	Also	if	the	concentration	is	higher	than	50ng/mL	and	the	cells	die	more	frequently,	
more	cells	will	not	survive	the	initial	cytokine	treatment	and	the	body	will	not	have	the	chance	
to	generate	an	anti-tumor	immune	response.	Therefore,	no	memory	of	the	cells	will	be	created	
by	the	adaptive	immune	system,	similar	to	current	treatments	with	chemotherapeutics.	
Chemotherapy	is	simply	aimed	to	kill	the	cells,	not	to	train	the	immune	system	in	detection	and	
removal	of	the	cells	on	its	own.	The	purpose	of	this	project	was	to	create	an	autologous	vaccine	
to	increase	the	immunogenicity	of	4T1	cells	therefore	generating	an	anti-tumor	immune	
response	by	the	body	for	future	tumor	growth.		
						Due	to	the	minimal	or	lack	of	increase	in	MHC	and	co-stimulatory	molecules	from	either	
cytokine,	a	new	method	needs	to	be	assessed	to	increase	the	immunogenicity	of	4T1	cells.	4T1	
cells	need	to	be	assessed	in	comparison	to	alternate	non-immunogenic	cell	lines	that	have	
current	effective	treatments.	Comparison	methods	should	include	surface	marker	expression	
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and	protein	expression	in	the	two	cell	lines.	EMT-6	is	a	non-immunogenic	mammary	breast	
cancer	cell	line	with	less	invasive	properties	when	compared	to	4T1	cells.		
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5.	Project	2:	G-CSF	Knockdown	Immunomodulation	of	Breast	Cancer	Cells	for	Whole	Tumor	
Cell	Vaccine	
	
5.1	Introduction	
	 EMT6	cells	and	4T1	cells	are	both	non	immunogenic,	TNBC,	mouse	cell	lines.	The	
difference	between	the	two	cell	lines	being	4T1	cells	are	more	aggressive	and	invasive.11	EMT6	
cells	created		a	vaccination	model	by	irradiating	EMT6	cells	to	create	a	primary	and	booster	
vaccine	delivered	10	days	apart.	After	given	a	live	tumor	challenge	10	days	after	the	booster	
vaccine,	80%	of	mice	survived	the	tumor	challenge.11	Through	the	same	protocol	for	a	4T1	
vaccine,	all	mice	failed	to	survive	the	live	tumor	challenge.12	A	combination	of	EMT6	and	4T1	
cells	injected	on	the	same	flank	as	well	as	opposite	flanks	has	also	been	performed.	Although	
the	live	tumor	challenge	resulted	in	60%	and	88%	of	mice	developing	tumors,	respectively.12	
Therefore,	it	was	clear	the	4T1	cell	line	is	expressing	a	specific	protein	that	diminishes	the	effect	
of	an	irradiation	4T1	vaccine.	
Due	to	the	addition	of	cytokines	not	having	a	large	effect	on	surface	marker	expression	
of	4T1	cells,	the	next	route	of	experiment	to	analyze	was	protein	expression.	This	was	verified	
by	previous	studies	performed	by	Ravindranathan,	et	al.	4T1	cells	and	EMT6	cells	express	
immunosuppressive	cytokines	including	G-CSF,	GM-CSF,	M-CSF,	IL-6,	MCP-1,	VEGF,	and	TGF-β.	
The	cytokines	are	expressed	in	different	amounts	as	well	as	comparing	before	and	after	
irradiation,	for	both	cell	lines.12	Cytometric	bead	array	and	ELISA	measured	the	amount	of	
cytokines	within	each	cell	line’s	media	at	24,	48,	and	96	hours.13,14	IL-6,	MCP-1,	TGF-	β,	and	
VEGF	are	secreted	at	higher	levels	in	EMT6	cells	while	GM-CSF	and	G-CSF	are	secreted	at	
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increased	levels	in	4T1.11	The	data	revealed	increased	levels	of	GM-CSF,	M-CSF	and	G-CSF	
expressed	by	4T1	cells.12	These	studies	were	used	to	determine	which	protein	to	knock	out	of	
the	4T1	genome.	G-CSF	displayed	the	largest	increase	in	both	irradiated	and	non-irradiated	4T1	
cells	when	compared	to	EMT6	(Figure	5).12	
	
	
	
	 4T1	Cells	Alone	 	 EMT-6	Cells	Alone	
	 4T1	Cells	+	Irradiation	 	 EMT-6	Cells	+	Irradiation	
	
Figure	5.	Sandwich	ELISA	results	from	examining	the	concentration	of	G-CSF	(blue)	in	EMT-6	
(green)	and	4T1	cells	both	alone	(darker	color)	and	irradiated	(lighter	color).	ELISA	performed	
for	multiple	time	periods:	24,	48,	72,	and	96	hours.12	
	
Granulocyte	colony-stimulating	factor	(G-CSF)	is	a	protein	within	cells	that	inhibit	
myeloid	derived	suppressor	cells	(MDSC)	from	differentiating	into	mature	immune	cells.		G-CSF	
has	many	functions	involving	immune	response,	including	the	ability	to	overcome	neutropenia,	
neutrophil	mobilization,	and	regulating	granulopoiesis.15	It	has	also	been	used	in	combination	
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with	chemotherapeutics	to	treat	advanced	cancer.16	Its	ability	to	regulate	basal	and	neutrophil	
production	allows	chemotherapy	to	be	used	without	dose-limiting	neutropenia.16	Although	it	
also	activates	and	repopulates	dormant	breast	cancer	stem	cells.16	G-CSF	has	many	effects	in	
the	body	relating	to	breast	cancer	regulation	although	I	focused	on	its	effect	on	MDSCs.		
The	MDSCs	are	prevalent	in	innate	and	adaptive	immune	response	due	to	their	
granulocytes	and	monocytes	production.15	MDSCs	down	regulate	antitumor	immunity	by	
inhibiting	T	cell	responses	and	supporting	tumor	progression.17	MDSCs	also	produce	factors	to	
promote	tumor	angiogenesis	and	lymphangiogenesis.18	The	accumulation	results	from	their	
inability	to	differentiate	into	mature	immune	cells,	caused	by	expression	G-CSF	in	4T1	cells.18	
4T1	cells’	G-CSF-causing	accumulation	of	MDSCs	causes	4T1	cells	to	be	non	immunogenic.	There	
may	be	other	factors	which	cause	the	non	immunogenicity	as	well.		
Due	to	the	protein,	G-CSF,	exhibiting	a	large	increase	in	4T1	cells,	the	removal	of	the	
protein	will	have	an	effect	on	the	cell	line’s	immunogenicity.	CRISPR/Cas9	will	remove	the	
protein	and	single	colony	expansion	will	generate	the	4T1.GCSF-		cell	line.	Therefore,	I	
hypothesize	that	knocking	down	the	G-CSF	protein	within	4T1	cells	will	enhance	their	
immunogenicity	and	form	the	basis	for	a	novel	breast	cancer	vaccine.	
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5.2	Methods	and	Materials	
5.2.1Cell	Culture.		
The	4T1	cell	line	is	a	mouse	mammary	breast	cancer	purchased	from	ATCC.	The	cells	were	
cultured	in	Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)	media	containing	90%	DMEM	stock,	
10%	fetal	bovine	serum,	1%	Penicilin	Streptomycin,	4500mg/L	glucose,	2mM	L-glutamine,	and	
1%	sodium	pyruvate.	The	cells	were	grown	in	incubation	at	37°C	with	monitored	5%	CO2	and	
H20	levels.	The	cells	are	stored	frozen	in	a	Thermo	Scientific	Liquid	Nitrogen	container	(Locator	
4)	until	needed.	The	cell	count	doubles	in	24	hours.	
5.2.2	Clustered	Regularly	Interspaced	Short	Palindromic	Repeats	(CRISPR)/Cas9.	
Gene	editing	technology,	CRISPR/Cas9,	was	used	to	edit	the	genome	of	4T1	cells.	A	protein,	G-
CSF,	was	removed	from	the	genome	of	4T1	mouse	mammary	breast	cancer	cells.	Cas9	is	a	
CRISPR-associated	protein	with	two	nuclease	domains	encoded	to	cleave	DNA	at	a	specific	site.	
	
Figure	6.	CRISPR/Cas9	schematic	provided	from	OriGene.19	
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5.2.2.1	G-CSF	Protein	Sequence	
The	amino	acid	base	sequence	which	codes	for	G-CSF	within	4T1	cells	was	found	
from	NCBI	and	the	guide	sequence	for	the	CRISPR/Cas9	guide	RNA	was	provided	online	
at	crispr.mit.edu.	Once	the	protein	was	found,	CSF3-mouse	gene	knockout	kit	via	CRISPR	
(KN303891)	was	purchased	from	Origene	(Figure	6	(1)).	
	
5.2.2.1	Amplify	Plasmid	and	Transfect	4T1	Cells	
The	plasmid	will	be	amplified	within	bacteria	using	a	maxiprep	kit	(Qiagen, Inc..	
The	298B	G-CSF	plasmid	comes	on	top	of	agar	in	a	vile.	It	is	spread	on	an	agar	plate	and	
incubated	for	24	hours	to	allow	for	replication.	A	single	colony	is	selected	and	added	to	
20mL	of	Lysogeny	Broth	(LB)	medium.	It	is	placed	on	a	shaker	plate	for	24	hours	to	
ensure	proper	mixing.		
Nucleic	acid	quantification	will	isolate	the	RNA	plasmid	from	the	e.coli.	The	
supernatant	of	the	solution	is	filtered	through	a	spin	column	and	centrifuged	for	10	
minutes	then	1	minute	at	13000rpm,	4	times.	A	spectrometer	machine	measures	the	
DNA	absorbance	at	OD260nm	and	protein	at	OD	280nm.	A	purified	plasmid,	lacking	the	
desired	protein	inside,	is	confirmed	with	the	equation:	𝑂𝐷260𝑂𝐷280 = 𝐴	𝑃𝑢𝑟𝑖𝑓𝑖𝑒𝑑	𝑝𝑟𝑜𝑡𝑒𝑖𝑛: 1.8 < 𝐴 < 2.0	
The	plasmid	is	visualized	using	gel	electrophoresis	techniques	and	a	UV	gel	
reader.	The	amplified	plasmid	will	be	added	into	a	flask	with	4T1	cells	where	the	plasmid	
will	inject	itself	into	the	nucleus	of	the	4T1	cells	via	lipofection.	Lipofectamine	3000	
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(Invitrogen,	Carlsbad,	CA)	is	used	to	transfect	the	4T1	cells	with	the	plasmid	DNA	and	
Cas9	enzyme.	1	million	cells/well	were	seeded	in	a	6	well	plate	for	24	hours.	Cells	were	
75%	confluent	in	a	T75	flask	upon	transfection.	Lipofectamine	3000	reagent	was	used,	
diluted	in	optimum	medium.	DNA	plasmid	was	diluted	to	become	1ug/uL,	
recommended	2uL	P3000/1mg	DNA.	Diluted	DNA	plasmid	and	diluted	lipofectamine	
3000	reagent	were	combined	and	incubated	at	room	temperature	for	5	minutes.	The	
DNA-lipid	complex	was	added	to	the	4T1	cells	in	the	6	well	plate	and	incubated	for	24	
hours.		
The	Cas9	enzyme	places	a	green	fluorescent	protein	(GFP)	where	the	target	gene	
is	knocked	out	(Figure	6	(3)).	The	GFP	signal	was	measured	using	a	Nikon	Eclipse	Ti	
fluorescent	microscope	and	images	were	captured	using	Nikon	NIS-Elements	BR	imaging	
software.	The	GFP	signal	will	verify	if	the	CRISPR/Cas9	knocked	out	G-CSF	from	4T1	cells.		
The	GFP	emitted	by	transfected	cells	will	allow	a	BD	FACS	ARIA	III	6-color	cell	
sorting	flow	cytometer	to	sort	the	4T1	and	4T1.GCSF-	cells.		The	remaining	4T1	altered	
genome	cell	culture	will	be	grown	and	tested	for	immunogenicity.		
	
5.2.3	Single	Colony	Selection.	
Single	colony	expansion	was	used	to	select	a	colony	developed	from	one	cell	of	the	
4T1.GCSF-	cell	line.	1000	4T1.GCSF-	cells	were	placed	on	a	petri	dish	and	cultured	for	24	hours.	
Colonies	were	viewed	under	a	microscope	and	selected	for	removal.	Grease	was	applied	to	the	
end	of	a	plastic	tube	and	placed	to	surround	a	specific	colony	to	isolate	it	from	the	remaining	
cells	in	the	petri	dish.	Trypsin	was	used	to	remove	the	cell	colony	from	the	petri	dish,	using	
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typical	trypsin	protocol.	The	colony	was	selected	and	placed	in	a	24	well	plate	to	expand	
further.	The	colony	was	transferred	to	a	6	well,	T25	flask,	and	finally	a	T75	flask	once	each	
container	reached	a	confluent	layer	of	the	4T1.GCSF-	colony.	Multiple	microcentrifuge	tubes	
containing	the	multiple	colonies	are	stored	at	-80ºC	in	a	Thermo	Scientific	Liquid	Nitrogen	
container	(Locator	4).	
	
5.2.4	Enzyme	Linked	Immunosorbent	Assay	(ELISA).	
Sandwich	ELISA	was	used	to	verify	that	G-CSF	was	knocked	out	of	the	4T1.GCSF-	cell	line.	
This	experiment	was	performed	in	triplicate.	The	G-CSF	(CSF3)	mouse	ELISA	kit	was	obtained	
from	R&D	Systems,	Inc.	(EMCSF3,	Minneapolis,	MN).	The	kit	includes	pre-coated,	pre-calibrated	
96	well	plates.	Standards	were	created	using	RD5-16	and	a	serial	dilution	from	stock	(900	
pg/mL).	50uL	of	RD1-54	and	50uL	of	standard,	control,	and	sample	are	added	to	the	pre-
assigned	wells	and	placed	in	incubation	at	room	temperature	for	2	hours	covered	with	an	
adhesive	strip.	The	plate	contents	are	discarded	and	washed	5	times	with	wash	buffer.	100uL	of	
mouse	G-CSF	conjugate	is	added	to	each	well	and	plate	is	incubated	for	2	hours	at	room	
temperature	covered	with	an	adhesive	strip.	The	plate	contents	are	discarded	and	washed	5	
times	with	wash	buffer.	100uL	of	the	substrate	solution	is	added	to	each	well	and	incubated	at	
room	temperature	for	30	minutes	covered	by	an	adhesive	strip	and	aluminum	foil	(light	
sensitive).	100uL	of	stop	solution	is	added	to	each	well	and	a	BioTek	Instruments	Synergy	2	
microplate	reader	(BioTek	Instruments,	Winooski,	VT)	measures	the	O.D.	at	450nm	and	540nm.	
The	540nm	O.D.	reading	is	subtracted	from	450nm	and	a	standard	curve	is	created	using	excel	
(R2	>.95).	The	concentration	of	G-CSF	samples	is	calculated	using	the	standard	curve	equation.	
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5.3	Results	
5.3.1	CRISPR/Cas9	
CRISPR/Cas9	removed	the	G-CSF	protein	from	the	4T1	mammary	mouse	breast	cancer	
cell	line.	The	amino	acid	base	sequence	which	codes	for	G-CSF	in	4T1	cells	was	identified	and	an	
RNA	sequence	in	plasmid	form	was	created.	The	plasmid	was	amplified	within	e.coli	using	a	
maxiprep	kit	and	added	to	a	flask	of	4T1	cells.	6	million	cells	were	transfected	with	CRISPR/Cas9	
targeted	genome	editing	technology.	Fluorescent	GFP	images	are	displayed	to	verify	cells	
express	the	Cas9	enzyme	which	has	removed	G-CSF	from	the	genome	(Figure	7).	The	large	
amount	of	GFP	fluorescence	correlates	with	a	large	efficiency	of	cells	being	transfected	with	the	
Cas9	enzyme.	Bright	field	and	GFP	fluorescent	images	are	taken	to	compare	the	number	of	
fluorescent	cells.	The	transfected	and	non	transfected	4T1	cells	were	separated	via	flow	
cytometry	cell	sorter	with	an	efficiency	of	3%.	This	efficiency	is	rather	low	compared	to	the	
fluorescent	images	although	the	flow	cytometer	may	have	detected	a	low	signal	for	GFP	in	cells	
and	sorted	them	as	non	transfected.	
	
	
	
	
	
	
Figure	7.	Fluorescent	and	bright	field	images	captured	using	Nikon	Imaging	Software.	GFP	was	
expressed	in	4T1	cells	that	up	took	the	RNA	plasmid.	
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Sandwich	ELISA	was	performed	to	verify	the	removal	of	G-CSF	from	the	4T1	genome	
after	the	sorted	4T1.GCSF-	cell	line	had	doubled	several	times.	The	cells	were	examined	and	had	
decreased	the	expression	of	G-CSF	by	almost	12	fold	(Figure	8).	The	results	reveal	several	cells	
lack	the	G-CSF	protein	although	some	4T1.GCSF-	continue	to	have	the	protein	expressed.	
Therefore,	it	was	necessary	to	continue	with	single	colony	selection	of	the	4T1.GCSF-	cell	line.				
	
	
	
	
	
	
	
	
Figure	8.	Sandwich	ELISA	performed	on	4T1	and	4T1	KO	cell	lines	to	compare	concentration	of	
the	protein	G-CSF	in	the	cells	(n=3).	4T1	KO	cells	were	tested	before	colony	selection.	
	
5.3.2	Single	Colony	Expansion	
	 Single	colony	expansion	was	performed	using	1000	4T1.GCSF-	cells	in	a	petri	dish.	A	
colony	of	cells	resulted	from	a	single	cell.	5	colonies	were	selected	and	removed	to	continue	
growth	in	a	larger	space.	Small	rubber	tubes	and	grease	was	used	to	separate	the	colonies	
while	assembling	them	for	continued	culture	(Figure	9).	The	cells	were	trypsinized	and	placed	in	
separate	flasks	to	grow	for	use	in	ELISA	to	test	for	complete	knock	out	of	G-CSF.	
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Figure	9.	Single	cell	colonies	were	isolated	inside	a	petri	dish	and	typsinized	for	uptake	and	
culture	in	larger	flasks.	5	colonies	were	selected.	
	 From	the	5	colonies	selected	for	continued	culture,	1	colony	was	used	for	ELISA	after	
colony	selection.	ELISA	verified	the	removal	of	G-CSF	from	the	4T1	cell	line	(Figure	10).	Each	
time	ELISA	was	performed,	the	4T1.GCSF-	after	selection	group	appeared	lower	than	detectable.	
A	4T1.GCSF-	cell	line	was	successfully	created.	
	
	
	
	
	
	
	
Figure	10.	Sandwich	ELISA	performed	on	4T1	and	4T1.GCSF-	cell	lines	both	before	and	after	
colony	selection	compared	concentrations	of	the	protein	G-CSF	in	the	cells	(n=3).	
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5.4	Discussions	and	future	work	
CRISPR/Cas9	is	revolutionary	technology	that	allows	removal	of	specified	genes	in	any	
genome.20	The	use	of	this	method	generated	the	4T1.GCSF-	cell	line.	In	the	future,	4T1.GCSF-	
and	4T1	cells	will	be	implanted	in	balb/c	female	mice	to	determine	if	knocking	out	G-CSF	
inhibited	the	ability	of	4T1	cells	to	induce	MDSC	proliferations.		The	cell	line	will	be	tested	to	
see	if	the	%	of	MDSCs	in	the	spleen	of	balb/c	female	mice	injected	with	4T1.GCSF-	has	
decreased	compared	to	4T1.	This	experiment	will	be	done	using	flow	cytometry	to	measure	the	
%	of	cells	in	the	spleen	that	are	characterized	as	MDSCs.		
After	it	has	been	verified	that	there	is	a	decrease	in	the	number	of	MDSCs	in	the	spleen,	
an	in-vivo	prophylactic	vaccination	will	occur.	4T1.GCSF-and	4T1	will	be	compared	in	a	
prophylactic	vaccination	study.	Groups	of	mice	will	receive	100,000	irradiated	4T1.GCSF-	or	4T1	
cells	on	days	0	and	10.		Mice	will	be	challenged	with	live	tumor	cells	on	day	20	and	tumor	
volumes	will	be	recorded	three	times	per	week.		
If	the	4T1.GCSF-	fails	to	give	a	similar	result	as	EMT-6	vaccinated	mice,	an	alternate	
experiment	may	be	performed	using	TNF-α	and	the	4T1.GCSF-	cell	line.	G-CSF	negates	the	effect	
of	TNF-α	in	the	body.21	The	previous	experiments	performed,	adding	cytokines	to	the	4T1	cells,	
should	be	repeated	with	4T1.GCSF-	to	see	if	a	different	result	is	observed.	There	was	a	minimal	
difference	in	the	addition	of	TNF-α	to	4T1	therefore	with	the	removal	of	G-CSF	there	could	be	a	
greater	and	more	impactful	effect	on	the	immunogenicity	of	the	cell	line.	If	the	4T1.GCSF-	cell	
line	does	not	provide	desired	results	as	predicted	for	the	in-vivo	prophylactic	vaccination,	an	
additional	in-vivo	prophylactic	vaccination	should	be	performed	with	the	4T1.GCSF-	cell	line	
with	cytokines.	
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